Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, prostate

1354 - Risk of prostate cancer mortality in men with an initial benign needle core biopsy set: a population based analysis with up to 20 years of follow-up


09 Oct 2016


Genitourinary tumours, prostate


Nina Klemann


Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372


N. Klemann1, J.T. Helgstrand1, K. Brasso1, B. Vainer2, B.G. Toft2, M.A. Røder1, P. Iversen1

Author affiliations

  • 1 Copenhagen Prostate Cancer Center, Rigshospitalet, Copenhagen University Hospital, 2200 - Copenhagen/DK
  • 2 Department Of Pathology, Rigshospitalet, Copenhagen University Hospital, 2200 - Copenhagen/DK


Abstract 1354


It has been questioned whether systematic transrectal ultrasound-guided biopsies (TRUS-gb) miss significant prostate cancers (PCa). MRI guided biopsies have been proposed for men where the initial TRUS-gb was normal and may increase sensitivity and detection of significant PCa, a definition based on the presence of a Gleason grade 4 or more in the biopsies. In 2010, Schröder et al. demonstrated with data from the ERSPC-study, that 0.03% of men with an initial, normal biopsy set died from PCa after 11 years of follow-up . Here, we calculate the risk of PCa specific mortality in men with an initial, benign biopsy set, in the complete nation-wide cohort of men who underwent evaluation for PCa with TRUS-gb during a 16-year period, in which systematic PSA screening or MRI was not part of the clinical setup.


Data originate from the Danish Prostate Cancer Register (DaPCaR). All men undergoing their first TRUS-gb in 1995-2011 were identified. Risk of PCa-specific mortality was analyzed in a competing risk setting treating death from non-PCa as competing risk.


64,430 men were referred for TRUS-gb. A total of 27,537 men had a benign first biopsy set, and 8,526 of these underwent a re-biopsy procedure. Median follow-up was 7.1 years. After 20 years, the estimated cumulative incidence of PCa mortality and other-cause mortality for all 64,430 included men was 25.6% and 50.5%, respectively. For men with an initial, benign TRUS-gb, the similar cumulative incidence of PCa mortality and other-cause mortality was 5.2% and 59.9% after 20 years, respectively. When stratified for level of PSA at time of referral, the estimated risk of PCa mortality after 15 years in men with a benign, first TRUS-gb was 0.7% for PSA ≤10 µg/L, 3.6% for PSA >10  20 µg/L.


Our data demonstrate, that the first systematic TRUS-gb does indeed diagnose patients at risk of PCa death. Our study supports the results from ERSPC, underlining that men with low PSA and an initial normal TRUS-gb rarely harbor lethal PCa. This information has implications for the future strategy of how to advise men with benign biopsies.

Clinical trial identification

Legal entity responsible for the study



The Danish Cancer Society, The Capital Region of Denmarks Fund for Health Research, Krista and Viggo Petersens Foundation


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings